Dual checkpoint blockade for microsatellite instability-high colorectal cancer

被引：0
作者：
Haldar, S. Daniel [1 ]
Kopetz, Scott [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77584 USA
来源：
LANCET | 2025年 / 405卷 / 10476期
关键词：
MISMATCH REPAIR-DEFICIENT; OPEN-LABEL; NIVOLUMAB;
D O I：
10.1016/S0140-6736(25)00144-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer
    Andre, Thierry
    Elez, Elena
    Van Cutsem, Eric
    Jensen, Lars Henrik
    Bennouna, Jaafar
    Mendez, Guillermo
    Schenker, Michael
    de la Fouchardiere, Christelle
    Limon, Maria Luisa
    Yoshino, Takayuki
    Li, Jin
    Lenz, Heinz-Josef
    Manzano Mozo, Jose Luis
    Tortora, Giampaolo
    Garcia-Carbonero, Rocio
    Dahan, Laetitia
    Chalabi, Myriam
    Joshi, Rohit
    Goekkurt, Eray
    Braghiroli, Maria Ignez
    Cil, Timucin
    Cela, Elvis
    Chen, Tian
    Lei, Ming
    Dixon, Matthew
    Abdullaev, Sandzhar
    Lonardi, Sara
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (21) : 2014 - 2026
  • [32] Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors
    Lengyel, Csongor Gyoergy
    CURRENT DRUG TARGETS, 2021, 22 (09) : 968 - 976
  • [33] Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer
    Sarshekeh, Amir Mehrvarz
    Overman, Michael J.
    Kopetz, Scott
    FUTURE ONCOLOGY, 2018, 14 (18) : 1868 - 1874
  • [34] Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer
    Pei, Fengyun
    Wu, Jingjing
    Zhao, Yandong
    He, Wan
    Yao, Qijun
    Huang, Meijin
    Huang, Jun
    CLINICAL COLORECTAL CANCER, 2023, 22 (01) : 85 - 91
  • [35] Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
    Overman, Michael J.
    Lonardi, Sara
    Wong, Ka Yeung Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael A.
    Van Cutsem, Eric
    McDermott, Ray
    Hill, Andrew
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca A.
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 773 - +
  • [36] Microsatellite Instability and Metastatic Colorectal Cancer - A Clinical Perspective
    Buchler, Tomas
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [37] Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High
    Middha, Sumit
    Yaeger, Rona
    Shia, Jinru
    Stadler, Zsofia K.
    King, Sarah
    Guercio, Shanna
    Paroder, Victoriya
    Bates, David Db
    Rana, Satshil
    Diaz, Luis A., Jr.
    Saltz, Leonard
    Segal, Neil
    Ladanyi, Marc
    Zehir, Ahmet
    Hechtman, Jaclyn F.
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 14
  • [38] Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer
    Liu, Tong
    Liu, Shuang
    Guan, Shangwei
    Tai, Yu
    Jin, Yao
    Dong, Mei
    JOURNAL OF CHEMOTHERAPY, 2023, 35 (08) : 745 - 752
  • [39] Evolving Strategies in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Esophagogastric Adenocarcinoma
    Balmaceda, Nicole Baranda
    Kim, Sunnie S.
    CURRENT ONCOLOGY REPORTS, 2025, 27 (02) : 81 - 94
  • [40] Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients
    Wu, Qing
    Wang, Ziming
    Luo, Yang
    Xie, Xianhe
    BMC IMMUNOLOGY, 2023, 24 (01)
12345